A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
This trial is active, not recruiting.
|Phase||phase 1/phase 2|
|Trial identifier||NCT00048217, T1249-105|
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.
Male or female participants at least 18 years old.
Inclusion Criteria: - Completion T1249-102; - Currently failing a T-20 containing regimen Exclusion Criteria: - Non-completion of T1249-102.
Call for more information